A disintegrin and metalloproteinase 17 (ADAM-17) has multiple pathophysiological functions in Alzheimer's disease (AD). However, the clinical relevance of ADAM-17 in AD is not clear yet.
Objective
This study aims to investigate the levels of circulating ADAM-17 and their association with AD.
Methods
This cross-sectional study recruited 40 normal cognition (NC) participants and 36 AD patients. Plasma ADAM-17 and biomarkers of neurodegeneration were determined. The association of plasma ADAM-17 with cognitive functions and biomarkers of neurodegeneration was analyzed.
Results
Plasma ADAM-17 levels were elevated in AD patients in comparison with NC subjects. Plasma ADAM-17 was positively associated with Clinical Dementia Rating (CDR) scores, but negatively associated with the Mini-Mental State Examination scores and Montreal Cognitive Assessment scores. Plasma ADAM-17 levels were positively associated with the levels of Aβ40, Aβ42, and p-Tau181.
Conclusions
These findings suggest a link between ADAM-17 and the pathogenesis of AD from a clinical perspective.
WangJGuBJMastersCL, et al.A systemic view of Alzheimer disease – insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol2017; 13: 612–623.
2.
JiaLQuanMFuY, et al.Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol2020; 19: 81–92.
3.
IttnerLMGötzJ. Amyloid-β and tau–a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci2011; 12: 65–72.
4.
EdwardsDRHandsleyMMPenningtonCJ. The ADAM metalloproteinases. Mol Aspects Med2008; 29: 258–289.
5.
BuxbaumJDLiuKNLuoY, et al.Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem1998; 273: 27765–27767.
6.
PeschonJJSlackJLReddyP, et al.An essential role for ectodomain shedding in mammalian development. Science1998; 282: 1281–1284.
7.
LammichSKojroEPostinaR, et al.Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A1999; 96: 3922–3927.
8.
KoikeHTomiokaSSorimachiH, et al.Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J1999; 343(Pt 2): 371–375.
9.
HartmannDde StrooperBSerneelsL, et al.The disintegrin/metalloprotease ADAM 10 is essential for notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet2002; 11: 2615–2624.
10.
BrouCLogeatFGuptaN, et al.A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell2000; 5: 207–216.
11.
HartlDMayPGuW, et al.A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease. Mol Psychiatry2020; 25: 629–639.
12.
IemmoloMGhersiGBivonaG. The cytokine CX3CL1 and ADAMs/MMPs in concerted cross-talk influencing neurodegenerative diseases. Int J Mol Sci2023; 24: 8026.
13.
MorgantiJMNashKRGrimmigBA, et al.The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease. J Neurosci2012; 32: 14592–14601.
14.
NashKRMoranPFinneranDJ, et al.Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration. Mol Ther2015; 23: 17–23.
15.
JiangSBhaskarK. Dynamics of the complement, cytokine, and chemokine systems in the regulation of synaptic function and dysfunction relevant to Alzheimer's disease. J Alzheimers Dis2017; 57: 1123–1135.
16.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
17.
SperlingRAAisenPSBeckettLA, et al.Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 280–292.
18.
LiYXiongCAschenbrennerAJ, et al.Item response theory analysis of the clinical dementia rating. Alzheimers Dement2021; 17: 534–542.
19.
PintoTCCMachadoLBulgacovTM, et al.Is the Montreal cognitive assessment (MoCA) screening superior to the Mini-mental state examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer's disease (AD) in the elderly?Int Psychogeriatr2019; 31: 491–504.
20.
JiaJXuJLiuJ, et al.Comprehensive management of daily living activities, behavioral and psychological symptoms, and cognitive function in patients with Alzheimer's disease: a Chinese consensus on the comprehensive management of Alzheimer's disease. Neurosci Bull2021; 37: 1025–1038.
21.
MoroneyJTBagiellaEDesmondDW, et al.Meta-analysis of the Hachinski ischemic score in pathologically verified dementias. Neurology1997; 49: 1096–1105.
22.
WilliamsBWMackWHendersonVW. Boston naming test in Alzheimer's disease. Neuropsychologia1989; 27: 1073–1079.
23.
FanDYJianJMHuangS, et al.Establishment of combined diagnostic models of Alzheimer's disease in a Chinese cohort: the Chongqing ageing & dementia study (CADS). Transl Psychiatry2022; 12: 252.
24.
LiWWWangZFanDY, et al.Association of polygenic risk score with age at onset and cerebrospinal fluid biomarkers of Alzheimer's disease in a Chinese cohort. Neurosci Bull2020; 36: 696–704.
25.
JiangHHampelHPrvulovicD, et al.Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol Neurodegener2011; 6: 69.
26.
SunQHampelHBlennowK, et al.Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. J Alzheimers Dis2014; 41: 877–886.
27.
BaiLSongNYuJ, et al.Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer's disease patients of Northern Han Chinese descent. Curr Alzheimer Res2013; 10: 57–62.
28.
JanelidzeSBarthélemyNRSalvadóG, et al.Plasma phosphorylated tau 217 and Aβ42/40 to predict early brain Aβ accumulation in people without cognitive impairment. JAMA Neurol2024; 81: 947–957.
29.
PalmqvistSTidemanPMattsson-CarlgrenN, et al.Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA2024; 332: 1245–1257.
30.
BarthélemyNRSalvadóGSchindlerSE, et al.Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med2024; 30: 1085–1095.
31.
LiuCCLiuCCKanekiyoT, et al.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol2013; 9: 106–118.
32.
HaneyMSPálovicsRMunsonCN, et al.APOE4/4 Is linked to damaging lipid droplets in Alzheimer's disease microglia. Nature2024; 628: 154–161.
33.
ChengXYangLHeP, et al.Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. J Alzheimers Dis2010; 19: 621–630.
34.
ShenYLiRShiosakiK.Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line. J Biol Chem1997; 272: 3550–3553.
